LU87229A1 - Nouveaux(omega-ammonio acyloxy methylene)-5 tetrahydrofuranes et tetrahydrothiophenes,un procede pour leur preparation et compositions therapeutiques en contenant - Google Patents

Nouveaux(omega-ammonio acyloxy methylene)-5 tetrahydrofuranes et tetrahydrothiophenes,un procede pour leur preparation et compositions therapeutiques en contenant Download PDF

Info

Publication number: LU87229A1
Authority: LU; Luxembourg
Prior art keywords: compound; formula; tetrahydrofurans; tetrahydrothiophenes; preparation
Prior art date: 1987-05-29

Application number

LU87229A

Other languages

English (en)

French (fr)

Inventor

Jean-Jacques Godfroid

Francoise Heymans

Pierre Braquet

Original Assignee

Scras

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-05-29

Filing date

1988-05-27

Publication date

1988-12-13

1988-05-27 Application filed by Scras filed Critical Scras

1988-12-13 Publication of LU87229A1 publication Critical patent/LU87229A1/fr

Links

239000000203 mixture Substances 0.000 title claims description 9
230000001225 therapeutic effect Effects 0.000 title claims description 6
238000000034 method Methods 0.000 title description 10
238000002360 preparation method Methods 0.000 title description 7
125000001570 methylene group Chemical class [H]C([H])([*:1])[*:2] 0.000 title 1
150000001875 compounds Chemical class 0.000 claims description 31
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
HRBGUGQWTMBDTR-UHFFFAOYSA-N 2,3,4-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC=C(S(Cl)(=O)=O)C(C(C)C)=C1C(C)C HRBGUGQWTMBDTR-UHFFFAOYSA-N 0.000 claims description 3
RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical class C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 claims description 3
150000001450 anions Chemical class 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
239000012442 inert solvent Substances 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000003884 phenylalkyl group Chemical group 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 4
-1 5-pyridinio pentanoyloxy-methylene Chemical group 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 description 3
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
MYNRDUPGBPOWQT-IDTAVKCVSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-[[3-hydrazinylpropyl(methyl)amino]methyl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CN(CCCNN)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MYNRDUPGBPOWQT-IDTAVKCVSA-N 0.000 description 1
LIHWMLGRCUKVLB-UHFFFAOYSA-N 1-chloro-2,3,4-trimethoxybenzene Chemical compound COC1=CC=C(Cl)C(OC)=C1OC LIHWMLGRCUKVLB-UHFFFAOYSA-N 0.000 description 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
YSXDKDWNIPOSMF-UHFFFAOYSA-N 5-chloropentanoic acid Chemical compound OC(=O)CCCCCl YSXDKDWNIPOSMF-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
241000219198 Brassica Species 0.000 description 1
235000003351 Brassica cretica Nutrition 0.000 description 1
235000003343 Brassica rupestris Nutrition 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010022714 Intestinal ulcer Diseases 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
108010003541 Platelet Activating Factor Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
230000002804 anti-anaphylactic effect Effects 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
229940114078 arachidonate Drugs 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
238000013475 authorization Methods 0.000 description 1
QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
108010015046 cell aggregation factors Proteins 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000544 cholinesterase inhibitor Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000010410 layer Substances 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000003328 mesylation reaction Methods 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
235000010460 mustard Nutrition 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
SMPAPEKFGLKOIC-UHFFFAOYSA-N oxolane;hydrochloride Chemical compound Cl.C1CCOC1 SMPAPEKFGLKOIC-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

LU87229A 1987-05-29 1988-05-27 Nouveaux(omega-ammonio acyloxy methylene)-5 tetrahydrofuranes et tetrahydrothiophenes,un procede pour leur preparation et compositions therapeutiques en contenant LU87229A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8712693		1987-05-29
GB878712693A GB8712693D0 (en)	1987-05-29	1987-05-29	Tetrahydrofurans etc

Publications (1)

Publication Number	Publication Date
LU87229A1 true LU87229A1 (fr)	1988-12-13

Family

ID=10618139

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU87229A LU87229A1 (fr)	1987-05-29	1988-05-27	Nouveaux(omega-ammonio acyloxy methylene)-5 tetrahydrofuranes et tetrahydrothiophenes,un procede pour leur preparation et compositions therapeutiques en contenant

Country Status (32)

Country	Link
US (1)	US5017588A (de)
JP (1)	JPH0631228B2 (de)
KR (1)	KR960005152B1 (de)
AR (1)	AR243885A1 (de)
AT (1)	AT395715B (de)
AU (1)	AU610789B2 (de)
BE (1)	BE1002146A3 (de)
CA (1)	CA1317959C (de)
CH (1)	CH674985A5 (de)
DE (1)	DE3818106A1 (de)
DK (1)	DK167532B1 (de)
ES (1)	ES2009924A6 (de)
FI (1)	FI89353C (de)
FR (2)	FR2615854B1 (de)
GB (2)	GB8712693D0 (de)
GR (1)	GR1000147B (de)
HK (1)	HK101790A (de)
IE (1)	IE61341B1 (de)
IN (1)	IN168799B (de)
IT (1)	IT1219698B (de)
LU (1)	LU87229A1 (de)
MA (1)	MA21289A1 (de)
MY (1)	MY103289A (de)
NL (1)	NL192203C (de)
NO (1)	NO170086C (de)
NZ (1)	NZ224775A (de)
OA (1)	OA08878A (de)
PT (1)	PT87585B (de)
SE (1)	SE466449B (de)
SG (1)	SG93790G (de)
TN (1)	TNSN88049A1 (de)
ZA (1)	ZA883731B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8701727D0 (en) *	1987-01-27	1987-03-04	Scras	Tetrahydrofuran derivatives
GB8712694D0 (en) *	1987-05-29	1987-07-01	Scras	Tetrahydrofurans etc
ES2010568A6 (es) *	1988-08-04	1989-11-16	Uriach & Cia Sa J	Procedimiento para la obtencion de derivados 2,5-disustituidos de tetrahidrofurano.
ES2013834A6 (es) *	1989-01-30	1990-06-01	Uriach & Cia Sa J	Procedimiento para la obtencion de derivados 4-sustituidos de 2-alcoxitetrahidrofurano.
US5118708A (en) *	1989-06-23	1992-06-02	Norwich Eaton Pharmaceuticals, Inc.	Use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective agents
US20110097352A9 (en) *	1992-01-29	2011-04-28	Pharmexa Inc.	Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
KR100326276B1 (ko) *	1999-12-14	2002-03-08	정명식	테트라하이드로푸란 유도체, 이의 제조방법 및 이를포함하는 항진균제

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1088880A (en) *	1964-11-18	1967-10-25	Vantorex Ltd	ª‡-cycloalkyleneimino-substituted esters
GB8701727D0 (en) *	1987-01-27	1987-03-04	Scras	Tetrahydrofuran derivatives
GB8712694D0 (en) *	1987-05-29	1987-07-01	Scras	Tetrahydrofurans etc

1987
- 1987-05-29 GB GB878712693A patent/GB8712693D0/en active Pending
1988
- 1988-05-20 AR AR88310910A patent/AR243885A1/es active
- 1988-05-20 NL NL8801315A patent/NL192203C/nl not_active IP Right Cessation
- 1988-05-23 GR GR880100342A patent/GR1000147B/el not_active IP Right Cessation
- 1988-05-23 IN IN455/DEL/88A patent/IN168799B/en unknown
- 1988-05-25 ZA ZA883731A patent/ZA883731B/xx unknown
- 1988-05-25 NZ NZ224775A patent/NZ224775A/en unknown
- 1988-05-25 CH CH1980/88A patent/CH674985A5/fr not_active IP Right Cessation
- 1988-05-26 MY MYPI88000561A patent/MY103289A/en unknown
- 1988-05-26 PT PT87585A patent/PT87585B/pt not_active IP Right Cessation
- 1988-05-26 SE SE8801964A patent/SE466449B/sv not_active IP Right Cessation
- 1988-05-26 GB GB8812488A patent/GB2205100B/en not_active Expired - Lifetime
- 1988-05-26 FI FI882475A patent/FI89353C/fi not_active IP Right Cessation
- 1988-05-27 OA OA59367A patent/OA08878A/xx unknown
- 1988-05-27 DK DK291088A patent/DK167532B1/da not_active IP Right Cessation
- 1988-05-27 NO NO882335A patent/NO170086C/no not_active IP Right Cessation
- 1988-05-27 IE IE159988A patent/IE61341B1/en not_active IP Right Cessation
- 1988-05-27 DE DE3818106A patent/DE3818106A1/de active Granted
- 1988-05-27 TN TNTNSN88049A patent/TNSN88049A1/fr unknown
- 1988-05-27 IT IT20773/88A patent/IT1219698B/it active
- 1988-05-27 LU LU87229A patent/LU87229A1/fr unknown
- 1988-05-27 AU AU16722/88A patent/AU610789B2/en not_active Ceased
- 1988-05-27 BE BE8800600A patent/BE1002146A3/fr active
- 1988-05-27 MA MA21531A patent/MA21289A1/fr unknown
- 1988-05-27 JP JP63128593A patent/JPH0631228B2/ja not_active Expired - Lifetime
- 1988-05-27 ES ES8801674A patent/ES2009924A6/es not_active Expired
- 1988-05-27 CA CA000567990A patent/CA1317959C/en not_active Expired - Fee Related
- 1988-05-28 KR KR1019880006343A patent/KR960005152B1/ko not_active Expired - Fee Related
- 1988-05-30 FR FR888807163A patent/FR2615854B1/fr not_active Expired - Lifetime
- 1988-05-30 FR FR888807164A patent/FR2615735B1/fr not_active Expired - Lifetime
- 1988-05-30 AT AT0140788A patent/AT395715B/de not_active IP Right Cessation
1990
- 1990-02-27 US US07/485,448 patent/US5017588A/en not_active Expired - Fee Related
- 1990-11-19 SG SG937/90A patent/SG93790G/en unknown
- 1990-12-06 HK HK1017/90A patent/HK101790A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IT1219698B (it)	1990-05-24
IT8820773A0 (it)	1988-05-27
NL192203C (nl)	1997-03-04
ZA883731B (en)	1989-02-22
DK167532B1 (da)	1993-11-15
AT395715B (de)	1993-02-25
FR2615854B1 (fr)	1990-12-28
KR960005152B1 (ko)	1996-04-22
SE8801964L (sv)	1988-11-30
DK291088D0 (da)	1988-05-27
NO170086C (no)	1992-09-09
NL8801315A (nl)	1988-12-16
AR243885A1 (es)	1993-09-30
NO882335L (no)	1988-11-30
DK291088A (da)	1988-11-30
GR1000147B (el)	1991-09-27
IE61341B1 (en)	1994-11-02
GB2205100B (en)	1990-08-15
JPH0631228B2 (ja)	1994-04-27
MA21289A1 (fr)	1988-12-31
FI882475A0 (fi)	1988-05-26
NO170086B (no)	1992-06-01
GR880100342A (en)	1989-02-23
TNSN88049A1 (fr)	1990-07-10
FI882475L (fi)	1988-11-30
BE1002146A3 (fr)	1990-07-31
US5017588A (en)	1991-05-21
FI89353B (fi)	1993-06-15
ES2009924A6 (es)	1989-10-16
SG93790G (en)	1991-01-18
HK101790A (en)	1990-12-14
NL192203B (nl)	1996-11-01
NZ224775A (en)	1990-01-29
MY103289A (en)	1993-05-29
FR2615735A1 (fr)	1988-12-02
JPS649988A (en)	1989-01-13
NO882335D0 (no)	1988-05-27
PT87585A (pt)	1989-05-31
IE881599L (en)	1988-11-29
CA1317959C (en)	1993-05-18
IN168799B (de)	1991-06-08
DE3818106A1 (de)	1988-12-15
FR2615854A1 (fr)	1988-12-02
ATA140788A (de)	1992-07-15
FR2615735B1 (fr)	1991-01-11
DE3818106C2 (de)	1993-07-01
AU1672288A (en)	1988-12-01
KR880013928A (ko)	1988-12-22
OA08878A (fr)	1989-10-31
FI89353C (fi)	1993-09-27
GB8712693D0 (en)	1987-07-01
PT87585B (pt)	1992-09-30
SE466449B (sv)	1992-02-17
AU610789B2 (en)	1991-05-23
CH674985A5 (de)	1990-08-15
GB8812488D0 (en)	1988-06-29
GB2205100A (en)	1988-11-30
SE8801964D0 (sv)	1988-05-26

Publication	Publication Date	Title
EP0099789B1 (de)	1987-07-29	3-Aminochinuclidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0233793B1 (de)	1992-04-01	Dekahydrochinolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende Zubereitungen
EP1708994B1 (de)	2007-08-08	Derivate vom aryloxyalkylcarbamat-typ, verfahren zu deren herstellung und deren verwendung in therapeutika
EP0382634B1 (de)	1994-05-04	Pyridazin-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
EP0684241A1 (de)	1995-11-29	N-pyridyl Carboxamidderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutischen Zusammensetzungen
EP0022118A1 (de)	1981-01-07	Sulfonyl-anilin-Derivate, Verfahren zu ihrer Herstellung und ihre therapeutische Verwendung
EP0037778A1 (de)	1981-10-14	2-(1,4-Benzodioxanyl)-methoxy-propanolamine, Verfahren zu deren Herstellung und Verwendung als Arzneimittel
EP0459887A1 (de)	1991-12-04	Pyrazolyl-orthodialkyl-Benzamid-Derivate mit antikonvulsiver Aktivität, Verfahren zur Herstellung und pharmazeutische Zusammensetzung
LU83293A1 (fr)	1981-12-02	Amines antihypertensives,leur procede de preparation et compositions antihypertensives en contenant
CA1131230A (fr)	1982-09-07	Procede de preparation de nouveaux derives de 1,3-dihydro3-/1-/2-(2,3-dihydro 1,4-benzodioxin-2-yl) 2-hydroxy-ethyl/piperidin-4-yl/2h-indol-2-one
CH674985A5 (de)	1990-08-15
EP0077720B1 (de)	1984-07-25	Derivate von Biphenyl-Alkyl-Carboxylaten, deren Herstellungsverfahren und deren Verwendung als Arzneimittel
LU87114A1 (fr)	1988-05-03	Nouveaux derives oxy-5 du tetrahydrofurane,un procede pour leur preparation et compositions therapeutiques en contenant
LU87230A1 (fr)	1988-12-13	Nouveaux methoxy-5 alcoyl ammonium tetrahydrofuranes et tetrahydrothiophenes,un procede pour leur preparation et compositions therapeutiques en contenant
EP0002635B1 (de)	1980-08-20	Verfahren zur Herstellung von Thieno (2,3-c)-bzw. (3,2-c) pyridinderivaten, so erhaltene Thieno (2,3-c) pyridinderivate und ihre therapeutische Anwendung
EP0201400B1 (de)	1989-07-19	4-Phenylpropylindolderivate und ihre Salze, Verfahren zur Herstellung, deren Anwendung als Heilmittel und sie enthaltende pharmazeutische Zusammensetzungen
FR2672286A1 (fr)	1992-08-07	Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
EP0101380A2 (de)	1984-02-22	N-substituierte Nicotinamid-1-oxyde, ihre Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
EP0772630B1 (de)	2001-09-19	Streptograminderivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen
EP0347305B1 (de)	1993-05-12	[(Aryl-4-piperazinyl-1)-2-ethoxy]-3p-cymole, die ortho-, meta-, para-monosubstituierten oder disubstituierten Derivate, das Verfahren zu deren Herstellung und die als aktives Prinzip diese Verbindungen enthaltenden Arzneimittel
EP0338937A2 (de)	1989-10-25	1-[3-(4-Hydroxy-phenyl)-1-hydroxy-1-propyl]-2-amino-alkylenoxy-benzen-Derivate und deren therapeutische Verwendung
FR2587333A1 (fr)	1987-03-20	Nouveaux ethers allyliques bicycliques, leur preparation et leur utilisation comme anti-fongiques et fongicides
EP0012072A2 (de)	1980-06-11	Von 2-Hydroxycyclopentancarbonsäure abgeleitete beta-Lactone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
CH623046A5 (de)	1981-05-15
EP0187096A1 (de)	1986-07-09	Arylalcoyloxymethyl-2-morpholine, deren Herstellung und deren Verwendung als Arzneimittel für die Behandlung von Zentralnervensystemstörungen